# Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

> **NCT06026917** · PHASE4 · UNKNOWN · sponsor: **Shanghai Mental Health Center** · enrollment: 15 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Toludesvenlafaxine hydrochloride sustained-release tablets

## Key facts

- **NCT ID:** NCT06026917
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-25
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026917, "Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06026917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*